Literature DB >> 20950327

Nanoparticulate systems for drug delivery and targeting to the central nervous system.

Emanuela Fabiola Craparo1, Maria Luisa Bondì, Giovanna Pitarresi, Gennara Cavallaro.   

Abstract

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotein inhibition. This review summarizes the main brain targeted nanoparticulate carriers such as liposomes, lipid nanoparticles, polymeric nanoparticles, and micelles with great potential in drug delivery into the CNS.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950327      PMCID: PMC6493787          DOI: 10.1111/j.1755-5949.2010.00199.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  58 in total

1.  Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system.

Authors:  A Friese; E Seiller; G Quack; B Lorenz; J Kreuter
Journal:  Eur J Pharm Biopharm       Date:  2000-03       Impact factor: 5.571

2.  Brain uptake of thiamine-coated nanoparticles.

Authors:  Paul R Lockman; Moses O Oyewumi; Joanna M Koziara; Karen E Roder; Russell J Mumper; David D Allen
Journal:  J Control Release       Date:  2003-12-12       Impact factor: 9.776

Review 3.  Advancing the field of drug delivery: taking aim at cancer.

Authors:  Marsha A Moses; Henry Brem; Robert Langer
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

4.  Drug delivery systems: entering the mainstream.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

5.  Body distribution of camptothecin solid lipid nanoparticles after oral administration.

Authors:  S Yang; J Zhu; Y Lu; B Liang; C Yang
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

Review 6.  Nanoparticulate systems for brain delivery of drugs.

Authors:  J Kreuter
Journal:  Adv Drug Deliv Rev       Date:  2001-03-23       Impact factor: 15.470

7.  Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.

Authors:  A E Gulyaev; S E Gelperina; I N Skidan; A S Antropov; G Y Kivman; J Kreuter
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

8.  Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.

Authors:  Jörg Kreuter; Dmitry Shamenkov; Valery Petrov; Peter Ramge; Klaus Cychutek; Claudia Koch-Brandt; Renad Alyautdin
Journal:  J Drug Target       Date:  2002-06       Impact factor: 5.121

Review 9.  Solid lipid nanoparticles for parenteral drug delivery.

Authors:  S A Wissing; O Kayser; R H Müller
Journal:  Adv Drug Deliv Rev       Date:  2004-05-07       Impact factor: 15.470

10.  Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.

Authors:  Jens Schmidt; Josbert M Metselaar; Marca H M Wauben; Klaus V Toyka; Gert Storm; Ralf Gold
Journal:  Brain       Date:  2003-06-04       Impact factor: 13.501

View more
  14 in total

1.  Sophorolipid Butyl Ester Diacetate Does Not Affect Macrophage Polarization but Enhances Astrocytic Glial Fibrillary Acidic Protein Expression at Micromolar Concentrations in Vitro.

Authors:  Alexis M Ziemba; Manoj K Gottipati; Filbert Totsingan; Cheryl M Hanes; Richard A Gross; Michelle R Lennartz; Ryan J Gilbert
Journal:  ACS Chem Neurosci       Date:  2017-02-07       Impact factor: 4.418

Review 2.  Handling of iron oxide and silver nanoparticles by astrocytes.

Authors:  Michaela C Hohnholt; Mark Geppert; Eva M Luther; Charlotte Petters; Felix Bulcke; Ralf Dringen
Journal:  Neurochem Res       Date:  2012-12-06       Impact factor: 3.996

3.  The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain.

Authors:  Lin Zhang; Limei Han; Jing Qin; Weiyue Lu; Jianxin Wang
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

Review 4.  Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.

Authors:  Benson J Edagwa; Tian Zhou; JoEllyn M McMillan; Xin-Ming Liu; Howard E Gendelman
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 5.  Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery.

Authors:  Gwen McCaffrey; Thomas P Davis
Journal:  J Investig Med       Date:  2012-12       Impact factor: 2.895

Review 6.  Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.

Authors:  Christos Tapeinos; Matteo Battaglini; Gianni Ciofani
Journal:  J Control Release       Date:  2017-08-26       Impact factor: 9.776

Review 7.  Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer's Disease.

Authors:  Pragya Girotra; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Simona Bungau
Journal:  J Mol Neurosci       Date:  2021-08-23       Impact factor: 3.444

8.  Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model.

Authors:  Elisa Salvati; Francesca Re; Silvia Sesana; Ilaria Cambianica; Giulio Sancini; Massimo Masserini; Maria Gregori
Journal:  Int J Nanomedicine       Date:  2013-05-06

9.  Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model.

Authors:  Sabrina Meister; Iavor Zlatev; Julia Stab; Dominic Docter; Sandra Baches; Roland H Stauber; Mordechai Deutsch; Reinhold Schmidt; Stefan Ropele; Manfred Windisch; Klaus Langer; Sylvia Wagner; Hagen von Briesen; Sascha Weggen; Claus U Pietrzik
Journal:  Alzheimers Res Ther       Date:  2013-11-27       Impact factor: 6.982

Review 10.  Nanoscale drug delivery systems and the blood-brain barrier.

Authors:  Renad Alyautdin; Igor Khalin; Mohd Ismail Nafeeza; Muhammad Huzaimi Haron; Dmitry Kuznetsov
Journal:  Int J Nanomedicine       Date:  2014-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.